Roberto Tirabosco
Royal National Orthopaedic Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Roberto Tirabosco.
The New England Journal of Medicine | 2011
Marjorie J. Lindhurst; Julie C. Sapp; Jamie K. Teer; Jennifer J. Johnston; Erin M. Finn; Kathryn F. Peters; Joyce T. Turner; Jennifer L. Cannons; David P. Bick; Laurel Blakemore; Catherine Blumhorst; Knut Brockmann; Peter Calder; Natasha Cherman; Matthew A. Deardorff; David B. Everman; Gretchen Golas; Robert M. Greenstein; B. Maya Kato; Kim M. Keppler-Noreuil; Sergei A. Kuznetsov; Richard T. Miyamoto; Kurt Newman; David Ng; Kevin O'brien; Steven Rothenberg; Douglas J. Schwartzentruber; Virender Singhal; Roberto Tirabosco; Joseph Upton
BACKGROUND The Proteus syndrome is characterized by the overgrowth of skin, connective tissue, brain, and other tissues. It has been hypothesized that the syndrome is caused by somatic mosaicism for a mutation that is lethal in the nonmosaic state. METHODS We performed exome sequencing of DNA from biopsy samples obtained from patients with the Proteus syndrome and compared the resultant DNA sequences with those of unaffected tissues obtained from the same patients. We confirmed and extended an observed association, using a custom restriction-enzyme assay to analyze the DNA in 158 samples from 29 patients with the Proteus syndrome. We then assayed activation of the AKT protein in affected tissues, using phosphorylation-specific antibodies on Western blots. RESULTS Of 29 patients with the Proteus syndrome, 26 had a somatic activating mutation (c.49G→A, p.Glu17Lys) in the oncogene AKT1, encoding the AKT1 kinase, an enzyme known to mediate processes such as cell proliferation and apoptosis. Tissues and cell lines from patients with the Proteus syndrome harbored admixtures of mutant alleles that ranged from 1% to approximately 50%. Mutant cell lines showed greater AKT phosphorylation than did control cell lines. A pair of single-cell clones that were established from the same starting culture and differed with respect to their mutation status had different levels of AKT phosphorylation. CONCLUSIONS The Proteus syndrome is caused by a somatic activating mutation in AKT1, proving the hypothesis of somatic mosaicism and implicating activation of the PI3K-AKT pathway in the characteristic clinical findings of overgrowth and tumor susceptibility in this disorder. (Funded by the Intramural Research Program of the National Human Genome Research Institute.).
The Journal of Pathology | 2011
M Fernanda Amary; Krisztian Bacsi; Francesca Maggiani; Stephen Damato; Dina Halai; Fitim Berisha; Robin Pollock; Paul O'Donnell; Anita Grigoriadis; Tim C. Diss; Malihe Eskandarpour; Nadège Presneau; Pancras C.W. Hogendoorn; Andrew Futreal; Roberto Tirabosco; Adrienne M. Flanagan
Somatic mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 occur in gliomas and acute myeloid leukaemia (AML). Since patients with multiple enchondromas have occasionally been reported to have these conditions, we hypothesized that the same mutations would occur in cartilaginous neoplasms. Approximately 1200 mesenchymal tumours, including 220 cartilaginous tumours, 222 osteosarcomas and another ∼750 bone and soft tissue tumours, were screened for IDH1 R132 mutations, using Sequenom® mass spectrometry. Cartilaginous tumours and chondroblastic osteosarcomas, wild‐type for IDH1 R132, were analysed for IDH2 (R172, R140) mutations. Validation was performed by capillary sequencing and restriction enzyme digestion. Heterozygous somatic IDH1/IDH2 mutations, which result in the production of a potential oncometabolite, 2‐hydroxyglutarate, were only detected in central and periosteal cartilaginous tumours, and were found in at least 56% of these, ∼40% of which were represented by R132C. IDH1 R132H mutations were confirmed by immunoreactivity for this mutant allele. The ratio of IDH1:IDH2 mutation was 10.6 : 1. No IDH2 R140 mutations were detected. Mutations were detected in enchondromas through to conventional central and dedifferentiated chondrosarcomas, in patients with both solitary and multiple neoplasms. No germline mutations were detected. No mutations were detected in peripheral chondrosarcomas and osteochondromas. In conclusion, IDH1 and IDH2 mutations represent the first common genetic abnormalities to be identified in conventional central and periosteal cartilaginous tumours. As in gliomas and AML, the mutations appear to occur early in tumourigenesis. We speculate that a mosaic pattern of IDH‐mutation‐bearing cells explains the reports of diverse tumours (gliomas, AML, multiple cartilaginous neoplasms, haemangiomas) occurring in the same patient. Copyright
The Journal of Pathology | 2006
Sonja Vujovic; Stephen Henderson; Nadège Presneau; Ts Jacques; Roberto Tirabosco; C Boshoff; Adrienne M. Flanagan
Chordomas are malignant tumours that occur along the spine and are thought to derive from notochordal remnants. There is significant morphological variability between and within chordomas, with some showing prominent areas of chondroid differentiation. Our microarray data from a broad range of connective tissue neoplasms indicate that, at the transcriptional level, chordomas resemble cartilaginous neoplasms. Here we show that chordomas express many genes known to be involved in cartilage development, but they also uniquely express genes distinguishing them from chondroid neoplasms. The brachyury transcription factor, known to be involved in notochordal development, is only expressed by chordomas. Using a polyclonal antibody, we show that brachyury is expressed in the embryonic notochord and in all 53 chordomas analysed, labelling both chondroid and chordoid areas of these tumours. In contrast, the protein was not detected in over 300 neoplasms, including 163 chondroid tumours. Brachyury was not detected in the nucleus pulposus, arguing against the hypothesis that this tissue derives directly from the notochord. These data provide compelling evidence that chordomas derive from notochord and demonstrate that brachyury is a specific marker for the notochord and notochord‐derived tumours. Copyright
Nature Genetics | 2013
Sam Behjati; Patrick Tarpey; Nadège Presneau; Susanne Scheipl; Nischalan Pillay; Peter Van Loo; David C. Wedge; Susanna L. Cooke; Gunes Gundem; Helen Davies; Serena Nik-Zainal; Sancha Martin; Stuart McLaren; Victoria Goodie; Ben Robinson; Adam Butler; Jon Teague; Dina Halai; Bhavisha Khatri; Ola Myklebost; Daniel Baumhoer; Gernot Jundt; Rifat Hamoudi; Roberto Tirabosco; M Fernanda Amary; P. Andrew Futreal; Michael R. Stratton; Peter J. Campbell; Adrienne M. Flanagan
It is recognized that some mutated cancer genes contribute to the development of many cancer types, whereas others are cancer type specific. For genes that are mutated in multiple cancer classes, mutations are usually similar in the different affected cancer types. Here, however, we report exquisite tumor type specificity for different histone H3.3 driver alterations. In 73 of 77 cases of chondroblastoma (95%), we found p.Lys36Met alterations predominantly encoded in H3F3B, which is one of two genes for histone H3.3. In contrast, in 92% (49/53) of giant cell tumors of bone, we found histone H3.3 alterations exclusively in H3F3A, leading to p.Gly34Trp or, in one case, p.Gly34Leu alterations. The mutations were restricted to the stromal cell population and were not detected in osteoclasts or their precursors. In the context of previously reported H3F3A mutations encoding p.Lys27Met and p.Gly34Arg or p.Gly34Val alterations in childhood brain tumors, a remarkable picture of tumor type specificity for histone H3.3 driver alterations emerges, indicating that histone H3.3 residues, mutations and genes have distinct functions.
Nature Genetics | 2011
M Fernanda Amary; Stephen Damato; Dina Halai; Malihe Eskandarpour; Fitim Berisha; Fiona Bonar; Stan McCarthy; Valeria Fantin; Kimberly Straley; Samira Lobo; Will Aston; Claire Green; Rosemary E. Gale; Roberto Tirabosco; Andrew Futreal; Peter J. Campbell; Nadège Presneau; Adrienne M. Flanagan
Ollier disease and Maffucci syndrome are characterized by multiple central cartilaginous tumors that are accompanied by soft tissue hemangiomas in Maffucci syndrome. We show that in 37 of 40 individuals with these syndromes, at least one tumor has a mutation in isocitrate dehydrogenase 1 (IDH1) or in IDH2, 65% of which result in a R132C substitution in the protein. In 18 of 19 individuals with more than one tumor analyzed, all tumors from a given individual shared the same IDH1 mutation affecting Arg132. In 2 of 12 subjects, a low level of mutated DNA was identified in non-neoplastic tissue. The levels of the metabolite 2HG were measured in a series of central cartilaginous and vascular tumors, including samples from syndromic and nonsyndromic subjects, and these levels correlated strongly with the presence of IDH1 mutations. The findings are compatible with a model in which IDH1 or IDH2 mutations represent early post-zygotic occurrences in individuals with these syndromes.
The American Journal of Surgical Pathology | 2008
Roberto Tirabosco; D. Chas Mangham; Andrew E. Rosenberg; Sonja Vujovic; Konstantinos Bousdras; Stefano Pizzolitto; Giovanna De Maglio; Michael A. den Bakker; Lisa Di Francesco; Ricardo K. Kalil; N A Athanasou; Paul O'Donnell; Edward F. McCarthy; Adrienne M. Flanagan
Axial chordoma represents approximately 1% of malignant bone tumors. This tumor expresses cytokeratins, specifically cytokeratin 19, and commonly S100. More recently brachyury, a transcription factor important in mesodermal differentiation, including notochord development, has been detected by immunohistochemistry in axial chordomas and hemangioblastomas but not chondrosarcomas or other neoplasms. In this report, we describe 10 cases (6 men, 4 women: age 18 to 68 y; mean 44.6) of extra-axial tumors, 8 in bone and 2 in soft tissue, with morphologic and immunohistochemical features identical to those of axial chordoma. Imaging excluded metastases from axial chordoma. Three tumors occurred in the tibia, the others in the rib, metatarsal, ulna, femur, pubis: 2 intracortical, 6 intramedullary. Both soft tissue brachyury-positive tumors, one involving the thumb the other the wrist, were sited in the juxta-articular region. Seven of the tumors were widely excised and these patients are disease-free but of the 3 tumors that recurred, 1 was curetted, 1 was marginally excised, and 1 had a pathologic fracture on presentation. Metastases have not occurred in any of the patients. We also confirm the expression of brachyury in hemangioblastomas, and for the first time demonstrates its expression in spermatogonia and testicular germ cell tumors by immunohistochemistry. Brachyury was not detected in a wide range of tumors including carcinomas, lymphomas, and sarcomas. In conclusion, we describe the first series of extra-axial skeletal chordomas bringing the total number of such cases reported in the literature to 11, and present the first report of 2 soft tissue chordomas as defined by brachyury expression.
Nature Genetics | 2013
Sharon A. Savage; Lisa Mirabello; Zhaoming Wang; Julie M. Gastier-Foster; Richard Gorlick; Chand Khanna; Adrienne M. Flanagan; Roberto Tirabosco; Irene L. Andrulis; Jay S. Wunder; Nalan Gokgoz; Ana Patiño-García; Luis Sierrasesúmaga; Fernando Lecanda; Nilgun Kurucu; Inci Ilhan; Neriman Sari; Massimo Serra; Claudia M. Hattinger; Piero Picci; Logan G. Spector; Donald A. Barkauskas; Neyssa Marina; Silvia Regina Caminada de Toledo; Antonio Sergio Petrilli; Maria Fernanda Amary; Dina Halai; David Thomas; Chester W. Douglass; Paul S. Meltzer
Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. To better understand the genetic etiology of osteosarcoma, we performed a multistage genome-wide association study consisting of 941 individuals with osteosarcoma (cases) and 3,291 cancer-free adult controls of European ancestry. Two loci achieved genome-wide significance: a locus in the GRM4 gene at 6p21.3 (encoding glutamate receptor metabotropic 4; rs1906953; P = 8.1 × 10−9) and a locus in the gene desert at 2p25.2 (rs7591996 and rs10208273; P = 1.0 × 10−8 and 2.9 × 10−7, respectively). These two loci warrant further exploration to uncover the biological mechanisms underlying susceptibility to osteosarcoma.
The Journal of Pathology | 2011
Nadège Presneau; Asem Shalaby; Hongtao Ye; Nischalan Pillay; Dina Halai; Bernadine Idowu; Roberto Tirabosco; Duncan Whitwell; Ts Jacques; Lars Gunnar Kindblom; Silke Brüderlein; Peter Möller; Andreas Leithner; Bernadette Liegl; Fernanda Amary; Nicholas N. Athanasou; Pancras C.W. Hogendoorn; Fredrik Mertens; Karoly Szuhai; Adrienne M. Flanagan
A variety of analyses, including fluorescence in situ hybridization (FISH), quantitative PCR (qPCR) and array CGH (aCGH), have been performed on a series of chordomas from 181 patients. Twelve of 181 (7%) tumours displayed amplification of the T locus and an additional two cases showed focal amplification; 70/181 (39%) tumours were polysomic for chromosome 6, and 8/181 (4.5%) primary tumours showed a minor allelic gain of T as assessed by FISH. No germline alteration of the T locus was identified in non‐neoplastic tissue from 40 patients. Copy number gain of T was seen in a similar percentage of sacrococcygeal, mobile spine and base of skull tumours. Knockdown of T in the cell line, U‐CH1, which showed polysomy of chromosome 6 involving 6q27, resulted in a marked decrease in cell proliferation and morphological features consistent with a senescence‐like phenotype. The U‐CH1 cell line was validated as representing chordoma by the generation of xenografts, which showed typical chordoma morphology and immunohistochemistry in the NOD/SCID/interleukin 2 receptor [IL2r]
Modern Pathology | 2007
Maria Fernanda Amary; Fitim Berisha; Fabíola Del Carlo Bernardi; Amanda Herbert; Michelle James; Jorge S. Reis-Filho; Cyril Fisher; Andrew G. Nicholson; Roberto Tirabosco; Timothy C. Diss; Adrienne M. Flanagan
\gamma^{\rm{null}}
Nature Communications | 2013
Paul Guilhamon; Malihe Eskandarpour; Dina Halai; Gareth A. Wilson; Andrew Feber; Andrew E. Teschendorff; Valenti Gomez; Alexander Hergovich; Roberto Tirabosco; M Fernanda Amary; Daniel Baumhoer; Gernot Jundt; Mark T. Ross; Adrienne M. Flanagan; Stephan Beck
mouse model. In conclusion, chromosomal aberrations resulting in gain of the T locus are common in sporadic chordomas and expression of this gene is critical for proliferation of chordoma cells in vitro. Copyright